Maruna P.:
Nitric oxide in hypothalamic-pituitary regulation I. Physiology
|
189 |
Vacek J.:
Mass spectrometry of intact tissue and its application in diagnostics
|
194 |
Pechandová K., Buzková H., Slanař O., Perlík F.:
Efflux transmembrane transporter – P-glycoprotein
|
196 |
Ondrkalová M., Kalnovičová T., Štofko J., Traubner P., Turčáni P.:
Levels of neuron-specific anolase in focal brain
ischaemia
|
202 |
Franeková J.1, Friedecký B.2, 4, Jabor A.3, Palička V.4, Stožický F.5, Soška V.6:
Reference intervals, optimal and target
values in the context of the clinical interpretation of lipid profile
|
207 |
Franeková J.1, 4, Jabor A.2, Friedecký B.3, Kubíček Z.4:
Lower cut-off for upper limit of fasting plasma glucose: what
does it mean?
|
211 |
Beránek M.1, Jandík P.2, Šácha M.3, Rajman M.3, Sákra L.3, Štumr F.4, Soudková E.4, Živný P.1, Havlíček K.3:
LNA clamped PCR: A specific method for detection
of Ki-ras gene mutations in patients with
sporadic colorectal carcinomas
Fulltext
|
217 |
Leníček M.1, Lukáš M.2, Budišová L.3, Jirsa M.1, 3, Kovář J.3, Donoval R.2, Bortlík M.2, Vítek L.1, 2Leníček M.1, Lukáš M.2, Budišová L.3, Jirsa M.1, 3, Kovář J.3, Donoval R.2, Bortlík M.2, Vítek L.1, 2:
Estimation of bile acid
malabsorption and the influence of CYP7A1 gene promoter polymorphisms
|
221 |
Engliš M.1, Jabor A.1, Kubáč P.2, Červinka I.3:
A contribution to the evaluation of metabolic component in acid-base
metabolism disorders according to Stewart and Fencl concept
|
225 |
Hrabovský V.1, Zadák Z.2, Bláha V.3, Hyšpler R.3, Tichá A.3, Karlík T.4:
Lipid metabolism in Crohn’s disease
|
228 |
Stejskal D.1, Fiala R.2:
Determination of the concentration of survivin and livin in serum or urine and the effective
diagnostics of bladder cancer
|
232 |
Ambrožová J.:
Discussion to the establishment of estimates for result uncertainties concerning the measurements
and clinical tests in clinical laboratories
|
236 |
